The role of iron supplementation during epoietin treatment for cancer-related anemia

Medical Oncology

Volumn 26, Issue 1, 2009, Pages 105-115

  Hedenus, M ^a   Birgegard G ^b  

^a SUNDSVALL HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anemia; Erythropoiesis; Erythropoietin; Hematinics; Iron

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS GLUCONATE; FERROUS SULFATE; IRON; IRON DERIVATIVE; IRON DEXTRAN; IRON FERRIC CARBOXYMALTOSE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; UNCLASSIFIED DRUG; ANTIANEMIC AGENT; DRUG DERIVATIVE; FERRIC CARBOXYMALTOSE; FERRIC ION; FERRIC OXIDE, SACCHARATED; FERROUS ION; MALTOSE;

ANAPHYLAXIS; ANEMIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; ERYTHROPOIESIS; FUNCTIONAL DISEASE; FUNCTIONAL IRON DEFICIENCY; HUMAN; INJECTION SITE DISCOLORATION; INJECTION SITE PAIN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON THERAPY; KIDNEY DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; THROMBOEMBOLISM; DRUG ADMINISTRATION; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; IRON INTAKE; NEOPLASM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIESIS; FERRIC COMPOUNDS; FERROUS COMPOUNDS; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; IRON COMPOUNDS; IRON, DIETARY; IRON-DEXTRAN COMPLEX; MALTOSE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 65549098896     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9072-0     Document Type: Review

References (89)

1. H Ludwig 2004 The European Cancer Anaemia Survey (ECAS): a large, multinational prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients Eur J Cancer 40 2293 306
2. JJ Caro M Salas A Ward G Goss 2001 Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review Cancer 91 2214 21
3. L Del Mastro 1997 Randomized phase III trail evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia J Clin Oncol 15 2715 21
4. D Bron N Meuleman C Mascaux 2001 Biological basis of anemia Semin Oncol 28 1 6
5. Nowrousian MR. Pathophysiology of cancer-related anemia. In: Nowrousian MR, editor. Recombinant human erythropoietin (rhEPO) in clinical oncology - scientific and clinical aspects of anemia in cancer. Springer: Wien; 2002. p. 39-62.
6. AM Konijn C Hershko 1977 Ferritin synthesis in inflammation. I. Pathogenesis of impaired iron release Br J Haematol 37 7 16
7. L Viatte 2006 Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice Blood 107 2952 8
8. S Rivera 2005 Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia Blood 105 1797 802
9. G Weiss LT Goodnough 2005 Anemia of chronic disease N Engl J Med 352 1011 23
10. CN Roy NC Andrews 2005 Anaemia of inflammation: the hepcidin link Curr Opin Haematol 12 107 11
11. F Locatelli 2004 Anemia management for hemodialysis patients: kidney disease outcomes quality initiative (K/DOQI) guidelines and dialysis outcomes and practice patterns study (DOPPS) findings Am J Kidney Dis 44 Suppl 2 S27 33
12. K Punnonen K Irjala A Rajamäki 1997 Serum transferrin receptor and its ration to s-ferritin in the diagnosis of iron deficiency Blood 89 1052 7
13. S Fishbane S Galgano RC Langley Jr W Canfield JK Maesaka 1997 Reticulocyte hemoglobin content in the evaluation or iron status of hemodialysis patients Kidney Int 52 217 22
14. IC Macdougall 1998 What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patients on rhEPO therapy? Merits of percentage of hypochromic red cells as a marker of functional iron deficiency Nephrol Dial Transplant 13 847 9
15. AE Mast MA Blinder Q Lu S Flax DJ Dietzen 2002 Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency Blood 99 1489 91
16. C Brugnara B Schiller J Moran 2006 Reticulocyte haemoglobin equivalent (Ret He) and assessment of iron-deficient states Clin Lab Haematol 28 303 8
17. C Thomas A Kirschbaum D Boehm L Thomas 2006 The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy Med Oncol 23 23 36
18. E Katodritou 2006 Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma Lab Hematol 12 47 54
19. E Katodritou 2007 Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma Ann Hematol 86 369 76
20. S Franck J Linssen M Messinger L Thomas 2004 Potential utility of Ret-Y in the diagnosis of iron restricted erythropoiesis Clin Chem 50 1240 2
21. DH Henry 1998 Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 3 275 8
22. D Cella 1998 Factors influencing quality of life in cancer patients: anemia and fatigue Semin Oncol 25 3 Suppl 7 43 6
23. J Crawford 2002 Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy Cancer 95 888 95
24. JD Rizzo 2008 Use of epoetin and darbepoetin in patients with cancer: 2007 ASH/ASCO clinical practice guideline update Blood 111 25 41
25. C Bokemeyer 2007 EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update Eur J Cancer 43 258 70
26. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Cancer- and treatment-related anemia. V.1.2008. http://www.nccn.org/ professionals/physician-gls/PDF/anemia.pdf.
27. J Mikhael B Melosky C Cripps D Rayson CT Kouroukis 2007 Canadian supportive care recommendations for the management of anemia in patients with cancer Curr Oncol 14 209 17
28. DH Henry 2007 Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies Drugs 67 175 94
29. CL Bennett 2008 Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia: JAMA 299 914 24
30. J Bohlius O Weingart S Trelle A Engert 2006 Cancer-related anemia and recombinant human erythropoietin - an updated overview Nat Clin Pract Oncol 3 152 64
31. M Henke 2003 Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial Lancet 362 1255 60
32. B Leyland-Jones 2005 Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study J Clin Oncol 23 5960 72
33. J Overgaard 2007 Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): the Danish Head and Neck Cancer Group DAHANCA 10 rand (abstract) Eur J Cancer 5 Suppl 7
34. JR Wright 2007 Randomized, double blind, placebo-controlled trial of erythropoietin in non-small-cell lungacancer with disease-related anemia J Clin Oncol 25 1027 32
35. RE Smith Jr 2008 Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase lll, multicenter, randomized, double-blind, placebo-controlled study J Clin Oncol 26 1040 50
36. M Mano 2005 Current role of erythropoietin in the management of patients with haematological and solid malignancies Cancer Ther 3A 41 56
37. J Glaspy I Cavill 1999 Role of iron in optimizing responses of anemic cancer patients to erythropoetin Oncology 13 461 73
38. I Cavill 2002 Iron and erythropoietin in renal disease Nephrol Dial Transplant 17 Suppl 5 19 23
39. I Cavill 2006 Iron and the anaemia of chronic disease: a review and strategic recommendations Curr Med Res Opin 22 731 7
40. G Vreugdendhil 1992 Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis Ann Hematol 65 265 8
41. J Goch G Birgegård BG Danielson B Wikström 1996 Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test Nephron 73 403 6
42. JH Savonije 2006 Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia Cancer Invest 24 562 6
43. S Fishbane GL Frei J Maesaka 1995 Reduction in recombinant human erythropoietin dose by the use of chronic intravenous iron supplementation Am J Kidney Dis 26 41 6
44. IC Macdougall 1999 Strategies for iron supplementation: oral versus intravenous Kidney Int 69 suppl S61 6
45. A Besarab S Frinak J Yee 1999 An indistinct balance: the safety and efficacy of parenteral iron therapy J Am Soc Nephrol 10 2029 43
46. C Gasche MC Lomer I Cavill G Weiss 2004 Iron, anaemia, and inflammatory bowel diseases Gut 53 1190 7
47. O Schröder 2005 Intravenous iron sucrose versus oral iron supplementation for treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, muticenter study Am J Gastroenterol 100 2503 9
48. Lindgren S, Befrits R, Wikman O, Hjortswang H. Intravenous iron sucrose compared to oral iron in anaemia management in IBD patients - a randomized, controlled, open label multicenter study. 14th UEGW Berlin 2006. Gut. 2006;55 Suppl Nov. (Abs).
49. N Bhandal R Russell 2006 Intravenous versus oral iron therapy for postpartum anaemia BJOG 113 1248 52
50. KDOQI Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(Suppl 3).
51. C Gasche 2007 Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases Inflamm Bowel Dis 13 1545 53
52. BG Danielson 2004 Structure, chemistry, and pharmacokinetics of intravenous iron agents J Am Soc Nephrol 15 S93 8
53. BG Danielson T Salmonson H Derendorf P Geisser 1996 Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers Drug Res 46 615 21
54. S Beshara 1999 Pharmacokinetics and red cell utilization of iron(lll) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography Br J Haematol 104 296 302
55. S Beshara 2003 Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anemic patients using positrob emission tomography Br J Haematol 103 853 9
56. JK Wood PFA Milner UN Pathak 1968 The metabolism of iron-dextran given as a total-dose infusion to iron deficient Jamaican subjects Br J Haematol 14 119 29
57. Y Beguin 2005 Intravenous iron and recombinant human erythropoietin in cancer patients J Clin Oncol 23 651 2
58. M Auerbach 2004 Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial J Clin Oncol 22 1301 7
59. Y Beguin 2005 Intravenous iron and recombinant human erythropoietin in cancer patients J Clin Oncol 23 651 3
60. DH Henry NV Dahl M Auerbach S Tchekmedyian LR Laufman 2007 Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy Oncologist 12 231 42
61. M Hedenus 2007 Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study Leukemia 21 627 32
62. G Birgegård L Wide B Simonsson 1989 Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation Br J Haematol 72 462 6
63. E Nemeth 2004 Il-6 mediates hypoferremia in inflammation by inducing the synthesis of the iron regulatory hormone, hepcidin J Clin Invest 113 1271 6
64. L Bastit 2008 Intravenous iron supplementation in patiens with chemotherapy-induced anemia receiving darbepoetin alfa every three weeks: iron parameters in a randomized controlled trial J Clin Oncol 26 1611 8
65. P Pedrazzoli A Farris S Del Prete 2008 Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha J Clin Oncol 26 1619 25
66. RE Bellet 2007 A phase 3 randomized controlled study comparing iron sucrose intravenously to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent therapy Proc Am Soc Clin Oncol 25 9109
67. Hedenus M, Näsman Per, Liwing J. Economic evalutation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. J Clin Pharmacy Therapeutics 2008 (in press).
68. Auerbach M, Pappadakis J, Doherty E. Therapeutic and financial optimization of anemia management in cancer patients with chemotherapy-related anemia through low molecular weight (LMW) iron dextran administration. Am Coll Clin Pharmacy Annual Meeting, Denver, Colorado. 2007;abs 188.
69. D Van Wyck J Anderson K Johnson 2004 Labile iron in parenteral formulations: a quantitative and comparative study Nephrol Dial Transplant 19 561 5
70. RA Zager AC Johnson SY Hanson H Wasse 2002 Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury Am J Kidney Dis 40 90 103
71. GR Bailie JA Clark CE Lane PL Lane 2005 Hypersensitivity reactions and deaths associated with intravenous iron preparations Nephrol Dial Transplant 20 1443 9
72. GM Chertow PD Mason O Vaage-Nilsen J Ahlmén 2006 Update on adverse drug events associated with parenteral iron Nephrol Dial Transplant 21 378 82
73. J Critchley Y Dundar 2007 Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review Transfus Altern Transfus Med 9 8 36
74. WH Hörl 2001 Should we still use iron dextran in hemodialysis patients? Am J Kidney Dis 37 859 61
75. P Grasso 1973 Sarcoma after intramuscular iron injection Br Med J 2 667
76. R Deicher F Ziai G Cohen M Müllner WH Hörl 2003 High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity Kidney Int 64 728 36
77. GR Aronoff 2004 Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens Kidney Int 66 1193 8
78. B Hoen A Paul-Dauphin D Hestin M Kessler 1998 EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients J Am Soc Nephrol 9 869 76
79. K Erichsen 2005 Oral versus intravenous iron therapy in patients with inflammatory bowel disease Scand J Gastroenterol 40 1 8
80. B Scheiber-Mojdehkar B Lutzky R Schaufler B Sturm H Goldenberg 2004 Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation J Am Soc Nephrol 15 1648 55
81. HI Feldman 2004 Administration of parenteral iron and mortality among hemodialysis patients J Am Soc Nephrol 15 1623 32
82. G Weiss VR Gordeuk 2005 Benefits and risks of iron therapy for chronic anaemias Eur J Clin Invest 35 Suppl 3 36 45
83. ED Weinberg 1996 The role of iron in cancer Eur J Cancer Prev 5 19 36
84. MD Kew 1990 Pathogenesis of hepatocellular carcinoma in hereditary hemochromatosis: occurrence in noncirrhotic patients Hepatology 11 1086 7
85. M Ali 1980 Hemosiderosis in hemodialysis patients. An autopsy study of 50 cases JAMA 244 343 5
86. N Le DR Richardsson 2002 The role of iron in cell cycle progression and the proliferation of neoplastic cells Biochim Biophys Acta 1603 31 46
87. K Merk 1990 The incidence of cancer among blood donors Int J Epidemiol 19 505 9
88. Zacharski LR, et al. Reducing iron stores lowers cancer risk in patients with peripheral arterial disease. Blood (ASH Annual Meeting Abstracts). 2007;110:2665.
89. K Kalantar-Zadeh DL Regidor CI McAllister B Michael DG Warmock 2005 Time-dependent associations between iron and mortality in hemodialysis patients J Am Soc Nephrol 3 772 89